Research on medical abortion gains traction in Latin America

30th November 2017

In a region where more than 97 percent of women of childbearing age live in countries where abortion is either restricted or banned altogether, Coalition-supported research on medical abortion is reaching receptive and influential audiences. Peru’s former Deputy Ombudsman for Women’s Rights and former Vice Minister of Public Health were among the audience of a recent introduction to an exciting new study “Mifepristone and misoprostol in six countries of Latin America: registration and availability processes”.

The study found that professional health association support and prior registration for obstetric use were positively associated with greater success in securing national regulatory approval of misoprostol and mifepristone for medical abortion. The Latin American Consortium Against Unsafe Abortion (CLACAI) conducted the research and documented cases of successful and failed registrations of misoprostol and mifepristone in six Latin American countries – Argentina, Brazil, Bolivia, Colombia, Peru, Uruguay. This work was made possible by a grant from the Innovation Fund, with financial support from the Norwegian Agency for Development Cooperation. About 100 participants attended, representing health and social sciences sectors from 15 countries. For more information, please contact Regional Advisor Milka Dinev at mdinev@rhsupplies.org

Categories: ForoLAC